Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | IDH1 | O75874 | 1/20 | 0.36 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.35 |
| ▸ | OPRL1 | P41146 | 5/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1698247 | 0.90 | CXCR4 (0.40) | CXCR4 | |
| SCHEMBL4350910 | 0.87 | CXCR4 (0.42) | CXCR4 | |
| SCHEMBL11923507 | 0.82 | DRD2 (0.40) | DRD2DRD3CXCR4OPRL1KCNH2 | |
| SCHEMBL14071365 | 0.80 | CYP2D6 (0.42) | DRD2DRD3CXCR4 | |
| SCHEMBL3315162 | 0.76 | CXCR4 (0.40) | CXCR4OPRL1KCNH2 | |
| SCHEMBL14893181 | 0.76 | OPRL1 (0.40) | CXCR4OPRL1KCNH2GRIN1GRIN2B | |
| SCHEMBL1698227 | 0.75 | CXCR4 (0.37) | DRD2DRD3CXCR4OPRL1KCNH2 | |
| SCHEMBL10367296 | 0.75 | CXCR4 (0.51) | DRD2CXCR4KCNH2 | |
| SCHEMBL6758153 | 0.74 | BCHE (0.59) | DRD2BCHE | |
| SCHEMBL13875279 | 0.73 | DRD2 (0.35) | DRD2DRD3CXCR4OPRL1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8933231-B2 | Organic compounds | GIVAUDAN SA | 2015-01-13 | — | — | US | disclosed |
| US-8933231-B2 | Organic compounds | GIVAUDAN SA | 2015-01-13 | — | — | US | disclosed |
| US-8933231-B2 | Organic compounds | GIVAUDAN SA | 2015-01-13 | — | — | US | disclosed |
| US-20130129655-A1 | Organic Compounds | GIVAUDAN SA (CH) | 2013-05-23 | — | — | US | disclosed |
| US-20130129655-A1 | Organic Compounds | GIVAUDAN SA (CH) | 2013-05-23 | — | — | US | disclosed |
| US-20130129655-A1 | Organic Compounds | GIVAUDAN SA (CH) | 2013-05-23 | — | — | US | disclosed |
| EP-2584916-A1 | ORGANIC COMPOUNDS | Givaudan SA (CH) | 2013-05-01 | — | — | EP | disclosed |
| WO-2011160254-A1 | ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2011-12-29 | — | — | WO | disclosed |
| WO-2011161163-A1 | ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2011-12-29 | — | — | WO | disclosed |
| WO-2011161163-A1 | ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2011-12-29 | — | — | WO | disclosed |
| WO-2011160254-A1 | ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2011-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130129655-A1 | Organic Compounds | C9, C5, TRPA1 | DRD2 750/4885DRD3 576/4885BCHE 2563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.